1
|
White AC and Lowry WE: Refining the role
for adult stem cells as cancer cells of origin. Trends Cell Biol.
25:11–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
O'Connor ML, Xiang D, Shigdar S, Macdonald
J, Li Y, Wang T, Pu C, Wang Z, Qiao L and Duan W: Cancer stem
cells: A contentious hypothesis now moving forward. Cancer Lett.
344:180–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Geng SQ, Alexandrou AT and Li JJ: Breast
cancer stem cells: Multiple capacities in tumor metastasis. Cancer
Lett. 349:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
6
|
Saadin K and White IM: Breast cancer stem
cell enrichment and isolation by mammosphere culture and its
potential diagnostic applications. Expert Rev Mol Diagn. 13:49–60.
2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Lee CH, Wu YT, Hsieh HC, Yu Y, Yu AL and
Chang WW: Epidermal growth factor/heat shock protein 27 pathway
regulates vasculogenic mimicry activity of breast cancer
stem/progenitor cells. Biochimie. 104:117–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Seftor RE, Hess AR, Seftor EA, Kirschmann
DA, Hardy KM, Margaryan NV and Hendrix MJ: Tumor cell vasculogenic
mimicry: From controversy to therapeutic promise. Am J Pathol.
181:1115–1125. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Jayakumar T, Hsu WH, Yen TL, Luo JY, Kuo
YC, Fong TH and Sheu JR: Hinokitiol, a natural tropolone
derivative, offers neuroprotection from thromboembolic stroke in
vivo. Evid Based Complement Alternat Med. 2013:8404872013.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Saeki Y, Ito Y, Shibata M, Sato Y, Okuda K
and Takazoe I: Antimicrobial action of natural substances on oral
bacteria. Bull Tokyo Dent Coll. 30:129–135. 1989.PubMed/NCBI
|
12
|
Shih YH, Lin DJ, Chang KW, Hsia SM, Ko SY,
Lee SY, Hsue SS, Wang TH, Chen YL and Shieh TM: Evaluation physical
characteristics and comparison antimicrobial and anti-inflammation
potentials of dental root canal sealers containing hinokitiol in
vitro. PLoS One. 9:e949412014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Shih MF, Chen LY, Tsai PJ and Cherng JY:
In vitro and in vivo therapeutics of β-thujaplicin on LPS-induced
inflammation in macrophages and septic shock in mice. Int J
Immunopathol Pharmacol. 25:39–48. 2012.PubMed/NCBI
|
14
|
Liu S and Yamauchi H: Hinokitiol, a metal
chelator derived from natural plants, suppresses cell growth and
disrupts androgen receptor signaling in prostate carcinoma cell
lines. Biochem Biophys Res Commun. 351:26–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Liu S and Yamauchi H: P27-Associated G1
arrest induced by hinokitiol in human malignant melanoma cells is
mediated via down-regulation of pRb, Skp2 ubiquitin ligase and
impairment of Cdk2 function. Cancer Lett. 286:240–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Ido Y, Muto N, Inada A, Kohroki J, Mano M,
Odani T, Itoh N, Yamamoto K and Tanaka K: Induction of apoptosis by
hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is
mediated through the activation of caspase-3. Cell Prolif.
32:63–73. 1999. View Article : Google Scholar : PubMed/NCBI
|
17
|
Muto N, Dota A, Tanaka T, Itoh N, Okabe M,
Inada A, Nakanishi T and Tanaka K: Hinokitiol induces
differentiation of teratocarcinoma F9 cells. Biol Pharm Bull.
18:1576–1579. 1995. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang WK, Lin ST, Chang WW, Liu LW, Li TY,
Kuo CY, Hsieh JL and Lee CH: Hinokitiol induces autophagy in murine
breast and colorectal cancer cells. Environ Toxicol. 2014.
|
19
|
Chang WW, Lin RJ, Yu J, Chang WY, Fu CH,
Lai A, Yu JC and Yu AL: The expression and significance of
insulin-like growth factor-1 receptor and its pathway on breast
cancer stem/progenitors. Breast Cancer Res. 15:R392013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Aranda E and Owen GI: A semi-quantitative
assay to screen for angiogenic compounds and compounds with
angiogenic potential using the EA. hy926 endothelial cell line.
Biol Res. 42:377–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ayakannu T, Taylor AH and Willets JM:
Validation of endogenous control reference genes for normalizing
gene expression studies in endometrial carcinoma. Mol Hum Reprod.
21:723–735. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Mohelnikova-Duchonova B, Oliverius M,
Honsova E and Soucek P: Evaluation of reference genes and
normalization strategy for quantitative real-time PCR in human
pancreatic carcinoma. Dis Markers. 32:203–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
McNeill RE, Miller N and Kerin MJ:
Evaluation and validation of candidate endogenous control genes for
real-time quantitative PCR studies of breast cancer. BMC Mol Biol.
8:1072007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Lipkowitz S: The role of the
ubiquitination-proteasome pathway in breast cancer: Ubiquitin
mediated degradation of growth factor receptors in the pathogenesis
and treatment of cancer. Breast Cancer Res. 5:8–15. 2003.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Authier F, Métioui M, Bell AW and Mort JS:
Negative regulation of epidermal growth factor signaling by
selective proteolytic mechanisms in the endosome mediated by
cathepsin B. J Biol Chem. 274:33723–33731. 1999. View Article : Google Scholar : PubMed/NCBI
|
27
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
28
|
Schneider BP and Miller KD: Angiogenesis
of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
30
|
Foekens JA, Peters HA, Grebenchtchikov N,
Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH,
Sweep CG and Klijn JG: High tumor levels of vascular endothelial
growth factor predict poor response to systemic therapy in advanced
breast cancer. Cancer Res. 61:5407–5414. 2001.PubMed/NCBI
|
31
|
Hoeben A, Landuyt B, Highley MS, Wildiers
H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth
factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Sasich LD and Sukkari SR: The US FDAs
withdrawal of the breast cancer indication for Avastin
(bevacizumab). Saudi Pharm J. 20:381–385. 2012. View Article : Google Scholar : PubMed/NCBI
|
33
|
Kirschmann DA, Seftor EA, Hardy KM, Seftor
RE and Hendrix MJ: Molecular pathways: Vasculogenic mimicry in
tumor cells: Diagnostic and therapeutic implications. Clin Cancer
Res. 18:2726–2732. 2012. View Article : Google Scholar : PubMed/NCBI
|
34
|
Silvan U, Diez-Torre A, Bonilla Z, Moreno
P, Diaz-Nunez M and Arechaga J: Vasculogenesis and angiogenesis in
nonseminomatous testicular germ cell tumors. Urol Oncol. 33:268
e217–228. 2015. View Article : Google Scholar
|
35
|
Alvero AB, Fu HH, Holmberg J, Visintin I,
Mor L, Marquina CC, Oidtman J, Silasi DA and Mor G: Stem-like
ovarian cancer cells can serve as tumor vascular progenitors. Stem
Cells. 27:2405–2413. 2009. View
Article : Google Scholar : PubMed/NCBI
|
36
|
Ricci-Vitiani L, Pallini R, Biffoni M,
Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G,
Larocca LM and De Maria R: Tumour vascularization via endothelial
differentiation of glioblastoma stem-like cells. Nature.
468:824–828. 2010. View Article : Google Scholar : PubMed/NCBI
|
37
|
Wang R, Chadalavada K, Wilshire J, Kowalik
U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C and
Tabar V: Glioblastoma stem-like cells give rise to tumour
endothelium. Nature. 468:829–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
38
|
Monzani E and La Porta CA: Targeting
cancer stem cells to modulate alternative vascularization
mechanisms. Stem Cell Rev. 4:51–56. 2008. View Article : Google Scholar : PubMed/NCBI
|
39
|
Chiao MT, Yang YC, Cheng WY, Shen CC and
Ko JL: CD133+ glioblastoma stem-like cells induce vascular mimicry
in vivo. Curr Neurovasc Res. 8:210–219. 2011. View Article : Google Scholar : PubMed/NCBI
|
40
|
Huang CH, Lu SH, Chang CC, Thomas PA,
Jayakumar T and Sheu JR: Hinokitiol, a tropolone derivative,
inhibits mouse melanoma (B16-F10) cell migration and in vivo tumor
formation. Eur J Pharmacol. 746:148–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
41
|
Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y
and Sun B: Thalidomide influences growth and vasculogenic mimicry
channel formation in melanoma. J Exp Clin Cancer Res. 27:602008.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Itzhaki O, Greenberg E, Shalmon B, Kubi A,
Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E,
Schachter J, et al: Nicotinamide inhibits vasculogenic mimicry, an
alternative vascularization pathway observed in highly aggressive
melanoma. PLoS One. 8:e571602013. View Article : Google Scholar : PubMed/NCBI
|